NCT04189588 2023-10-06
versus
TerSera Therapeutics LLC
Phase 2 Completed
Clinical Trials
8 trialsNCT00168727 2023-08-23
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
Biogen
Phase 4 Completed
NCT01448928 2021-10-01
ZEVALIN-DUI
Spectrum Pharmaceuticals, Inc
Completed
NCT00220285 2014-12-30
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma
Bayer
Phase 2 Completed
NCT00505232 2012-01-02
LCM-04-02
CABYC
Phase 2 Completed
NCT01479387 2011-11-24
ZEVALIN-SDUI
Bayer
Completed
NCT01164696 2010-08-24
A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin
Bayer
Completed
NCT00185393 2008-12-01
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
Bayer
Phase 3 Completed